PRMT5 and breast cancer: Given that PRMT1 and PRMT5 are currently the PRMTs known to contribute the most to BC development and treatment resistance, the primary focus of this review is to specifically highlight the current knowledge regarding their involvement in BC and the emerging therapeutic potential of targeting these enzymes to control disease recurrence, metastasis, and clinical outcome according to BC subtype.